PREMIER PRIX, PRIX D'EXCELLENCE DE LA SCOAuthor: Jordan IsenbergAuthor Disclosure Block: J. Isenberg: None.Abstract Body:Purpose: Ocular toxoplasmosis (OT) is the most common etiology of posterior uveitis. The high incidence of macular scarring associated with OT is a leading cause of visual morbidity. Serum biomarkers of the disease would aid in its diagnosis. This study sough...

Jordan Isenberg MD

Participant.e

Authors: Andrei F. Dan, Christian El-Hadad, Eric Fortin, Karin Oliver Author Disclosure Block: A.F. Dan: Employment/honoraria/consulting fees; Name of Commercial Company(s); ZenXMed. C. El-Hadad: None. E. Fortin: Grant/research support; Name of Commercial Company(s); AbbVie,Allergan. Employment/honoraria/consulting fees; Name of Commercial Company(s); AbbVie, Allergan, Alcon/Novartis. K. Oliver: None. Abstract Body: Purpose: First-visit q...

Andrei F. Dan

Participant.e

Authors: Solin Saleh, Chris Welsh, Chloe Gottlieb Author Disclosure Block: S. Saleh: None. C. Welsh: None. C. Gottlieb: None. Abstract Body: Purpose: Ozurdex (Allergan, Inc, Irvine, California) is a sustained-release intravitreal dexamethasone implant that delivers corticosteroid directly to the posterior segment of the eye, allowing for controlled drug release over approximately 6 months. To date, few studies have been carried out to ass...

Solin Saleh, MD, FRCSC MD

Participant.e

Authors: Zainab Khan, Julie Vadboncoeur, Yasmine Rabia, Bouchra Serhir, Annie-Claude Labbé, Claude Fortin, Kinda Najem, Laurence Jaworski, Marie-Josée Aubin Author Disclosure Block: Z. Khan: None. J. Vadboncoeur: None. Y. Rabia: None. B. Serhir: None. A. Labbé: None. C. Fortin: None. K. Najem: None. L. Jaworski: None. M. Aubin: Grant/research support; Name of Commercial Company(s); AbbVie. Employment/honoraria/consulting fees; Name of Commercial Company(s); Gilead. Membershi...

Dr. Zainab Khan

Participant.e